Choosing ImmunotherapyVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.
Listen as Dr. Michaelis discusses the unique aspects of the system burdens of polycythemia vera, the difficult approach to treat and the options to treat.Supported through funding from Incyte
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.